Compositions and methods to prevent AAV vector aggregation
US7704721B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2005 |
| Grant date | Apr 27, 2010 |
| Priority date | — |
| Expiry date | Jun 1, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14151
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for preparation of concentrated stock solutions of AAV virions without aggregation. Formulations for AAV preparation and storage are high ionic strength solutions (e.g. μ˜500 mM) that are nonetheless isotonic with the intended target tissue. This combination of high ionic strength and modest osmolarity is achieved using salts of high valency, such as sodium citrate. AAV stock solutions up to 6.4×1013 vg/mL are possible using the formulations of the invention, with no aggregation being observed even after ten freeze-thaw cycles. The surfactant Pluronic® F68 may be added at 0.001% to prevent losses of virions to surfaces during handling. Virion preparations can also be treated with nucleases to eliminate small nucleic acid strands on virions surfaces that exacerbate aggregation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.